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Abstract
Objectives:
To assess the level of pain intensity at which patients feel the impetus to ask for a breakthrough cancer pain
(BTcP) medication, and level of pain intensity at which patients consider they have achieved acceptable pain
control after receiving a BTcP medication.
Methods:
A consecutive sample of patients who were receiving oral morphine equivalents equal to or more than 60mg
daily, and were prescribed rapid onset opioids for the management of episodes of BTcP, were included in
the study. Focused educational activities regarding BTcP and numerical scales were established during
hospital admission. At discharge patients were interviewed to find out what was the pain intensity level
which gave the impetus to take the BTcP m dication, what was the pain intensity for acceptable pain control
after a BTcP medication had been given, and which factors prevented the patient calling for BTcP
medication. A brief COPE (coping orientation to problems experienced) questionnaire was also administered.
Results:
Fifty-two patients were recruited for this study. The meaningful pain intensity for asking for a BTcP
medication was 7.1; 77% of patients had a pain intensity of 7–8 on a numerical scale of 0–10. The
meaningful pain intensity for adequate analgesia after a BTcP medication was 3.5. Similarly, 77% of patients
had a pain intensity of 3–4. There was no relationship with the variables examined. Concerns by patients
about th use of BTcP medications were minimal.
Conclusion:
The meaningful BTcP intensity and pain intensity expected after BTcP medication can be useful in selecting
patients in studies of BTcP. The principal limitation of this study was the specific setting of an acute unit with
specific features and the relatively low number of patients. This observation should be followed up by further
surveys with a larger number of patients and different settings.
Introduction
Breakthrough cancer pain (BTcP) has been defined as ‘‘a transient exacerbation
of pain that occurs either spontaneously, or in relation to a specific trigger,
despite relatively stable and adequately controlled background pain’’1,2. BTcP
is often managed with opioids that are given in addition to regularly scheduled,
around-the-clock analgesics.
To evaluate the effects of an analgesic drug, pain intensity is commonly
measured at intervals after the administration. The time to effective pain
relief is a measure that has been recently used to better reflect the temporal
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aspects of pain incorporating a subjective component to
the measure3. This is a very important aspect as treatment
is dependent on the clinical judgment of patients4,5. This
parameter has been also used for controlled studies to com-
pare the rapidity of the analgesic effects of different fenta-
nyl formulations. This is obviously dependent on the
characteristics of the drug administered. For example the
median time to onset of meaningful pain relief was signif-
icantly shorter in patients receiving oral transmucosal fen-
tanyl citrate (about 15 minutes) than in patients receiving
oral opioids (more than 30 minutes)3, and was 11 minutes
for intranasal fentanyl6.
However, the pain intensity at time of meaningful pain
relief has never been assessed. In the measurement of
cancer pain exacerbations, patients commonly use numer-
ical rating scales more appropriately than verbal scales7.
Numerical scales have been commonly used as a single
entity, percentage pain intensity difference, the sum of
pain intensity differences, pain relief, and percentage of
maximum total pain relief. In the last decade scientists
tried to define a clinically important difference in pain
outcome measure and found that the best cut-off points
to define clinical difference in pain intensity was a pain
intensity difference of 2 points, a pain relief difference of 2
points, and a sum of the pain difference of 2 points. The
best cut-off point for both the percentage of maximum
pain relief and percentage pain intensity difference was
33%8. These measures have been invariably used in
many clinical trials to evaluate the effects of BTcP medi-
cations. However, levels of pain do not always fit these
figures. For example changes in pain intensity may differ
from 9 to 6, or from 6 to 4.
Moreover, many controlled studies often included
patients with mild to moderate pain having BTcP episodes
of moderate to severe pain, where there are more proba-
bilities of overlapping pain intensities which conversely
may influence the results obtained with the study drug9,
providing misleading data regarding the drug efficacy (for
example increasing the placebo effect) or even the need of
dose titration consequent to a lack of relationship between
the dose of background opioid regimen and the successful
dose for BTcP1. Thus, the level of pain intensity which is
considered acceptable for patients at time of meaningful
pain relief could be important to provide a common
parameter as it expresses a relevant individual measure.
Of interest, the pain intensity of a BTcP event has been
largely reported with pain intensity ranging from mild to
excruciating pain. This variability in selecting patients has
been reported as a confounding factor in many clinical
trials where fluctuations of pain of moderate intensity,
which could potentially disappear spontaneously, may be
treated as they would BTcP episodes1. This level of pain
intensity is the indicator to decide whether and when to
administer a BTcP medication. The severity of pain con-
sidered to be deserving an intervention from individuals
has never been explored. Patients’ impetus for taking BTcP
medication is variable as well as patients’ reasons for not
always taking BTcPmedication, including lack of intensity
of pain, adverse effects and concerns about adverse
effects2. For most studies of BTcP a pain of moderate to
severe intensity (5–10/10 on a numerical scale from 0 to
10) has been considered as an inclusion criteria10. In other
studies more stringent criteria were adopted, patients being
invited to call for administration of study medication when
pain is considered severe (7–10/10)1,9.
The aim of this study was to assess the individual level
of pain intensity at which patients feel the impetus to seek
for BTcP medication, and level of pain intensity at which
patients achieve acceptable pain control after receiving
BTcP medication.
Patients and methods
All the patients admitted to a Pain Relief and Palliative
Care unit in a period of 10 months, from March 2011 to
December 2011, were surveyed. From this sample, patients
who were receiving opioids in doses of oral morphine
equivalents equal to or more than 60mg daily, and were
prescribed rapid onset opioids (ROOs) for the manage-
ment of BTcP, were included into the study. Informed
consent and institutional approval were obtained.
Patients with cognitive disturbances or who died during
admission were excluded.
Patients were treated according to the department
policy. After achieving adequate analgesia, patients were
encouraged to call when they felt that their pain increased
in a significant way compared to their basal pain.
Written orders for BTcP, including drugs and doses to
be administered, are routinely given in the therapy chart.
As a routine, for each episode, trained nurses recorded pain
intensity and adverse effects severe enough in intensity to
require medical intervention, when called for pain
increases considered to be severe in intensity by patients
and 15 minutes after administering the rescue dose of opi-
oids. A physician on duty is present in the department, and
the palliative care team is available on call for any emer-
gency or consultation in case of development of severe
adverse effects. Educational activities regarding BTcP
and numerical scales were established during hospital
admission, particularly focusing on their experience and
the changes in pain intensity observed after administering
the BTcP medication.
At discharge patients who had their background pain
controlled (pain intensity of 4/10 on a numerical scale
from 0 to 10) were interviewed to answer the following
questions:
(a) After your experience with BTcP and medications
given for that, what is the pain intensity level (on a
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numerical scale from 0–10) which gives impetus to
take the BTcP medication?
(b) What is the pain intensity level (on a numerical scale
from 0–10) which provides acceptable pain control
after a BTcP medication is given?
(c) What prevents you from calling for BTcP medica-
tion: concerns about adverse effects, low level of
pain intensity, BTcP medication considered ineffec-
tive, episode of pain too short, other reasons.
Level of education was also collected (primary school,
secondary school, degree). A brief COPE (coping orienta-
tion to problems experienced) questionnaire was also
administered11. Psycho-oncologists, expert in interpreting
the items from the questionnaire, provided three general
coping profiles: problem focused, emotion focused,
avoidance.
Statistical analysis
Statistical analysis of quantitative and qualitative data,
including descriptive statistics, was performed for all the
items. Frequency analysis was performed with the chi-
square test. Continuous data were expressed as
mean standard deviation, unless otherwise specified.
One-way analysis of variance (ANOVA) was conducted
to analyze the possible relationship between clinical vari-
ables and meaningful pain intensity for BTcP.
Data were analyzed by Epi Info software (version 6.0,
CDC, Atlanta, GA, USA) and SPSS Software 14.0 ver-
sion (SPSS Inc., Chicago, IL, USA). All P values were
two-sided and P values less than 0.05 were considered to
indicate statistical significance.
Results
All the screened patients were available for the study, and
data from fifty-two patients were available. Patient char-
acteristics are presented in Table 1. Twenty-eight patients
were males, and the mean age was 58.6 years (SD 10.8).
The mean Karnofsky performance status was 50.3 (SD
10.4). The median admission time was 5 days and a
median of nine breakthrough pain events for each patient
were treated during that time. At time of discharge the
background pain intensity was 2.6 (SD 1.4). Opioids and
doses prescribed for background analgesia are shown in
Table 2. Drugs and doses prescribed for BTcP are shown
in Table 3. The meaningful pain intensity for asking for a
BTcP medication was 7.11 (SD 0.8). The majority of
patients (77%) had a pain intensity of 7/10 (n. 21) or 8/
10 (n.19). The meaningful pain intensity for adequate
analgesia after a BTcP medication was 3.5 (SD 1.04).
The majority of patients (77%) had a pain intensity of
4/10 (n. 27) or 3/10 (n.13).
There was no relationship with the variables examined
(Table 4). Only 12 patients were concerned about seeking
BTcP medication, for the following reasons: low pain
intensity (2 patients), the short duration of effect
(2 patients), inefficacy (1 patient), fear of adverse effects
(3 patients), other reasons (4 patients).
Discussion
Many controlled studies of ROOs for the management of
BTcP have reported significant differences in pain inten-
sity and onset in comparison with placebo or oral opioids.
Populations included in these trials, however, were quite
non-homogeneous in terms of levels of pain intensity, as
patients were often included without a clear distinction
between the BTcP intensity and background pain.
Table 3. Drugs and doses prescribed for BTcP.
Frequency Mean dose (SD)
Oral morphine 9 28mg (48)
Fentanyl buccal tablets 19 616mg (602)
Pectyn–fentanyl nasal spray 3 433mg (351)
Intranasal fentanyl 5 220mg (110)
Sublingual fentanyl tablets 5 420mg (110)
Intravenous morphine 1 5.0mg
Oxycodone–paracetamol 4 7.5mg (2.9)
Oral transmucosal fentanyl 3 1133 mg (1137)
NSAIDs 2
Tramadol 1
BTcP¼ breakthrough cancer pain, NSAIDs¼ non-steriodal anti-inflamma-
tory drugs.
Table 2. Opioids and doses prescribed for background analgesia.
Frequency Mean dose,
mg/day (SD)
SR oral morphine 6 257 (331)
Oral methadone 5 64 (56)
SR oral hydromorphone 17 73 (74)
SR oral oxycodone/naloxone 3 37 (6)
Transdermal fentanyl 10 1.9 (1.6)
Transdermal buprenorphine 3 0.9 (0.6)
SR oral oxycodone 3 60 (35)
Multiple opioids or
combination with non-opioid
5
SR¼ sustained release.
Table 1. Patient characteristics.
Age, mean (SD) 58.6 (10.8)
Gender (F/M) 24/28
Primary tumor:
lung 10
urogenital 10
pancreas 8
gastrointestinal 8
breast 8
head & neck 2
others 6
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Some patients had relatively high levels of background
pain and some others had low level of BTcP1,9,10. This
bias has often amplified the effects of the comparison sub-
stances, either placebo or oral opioids. Daily fluctuations of
pain intensity may induce patients to treat them as they
would episodes of BTcP, for example with ROOs, and the
spontaneous course of pain fluctuations may render the
interpretation more difficult.
For this reason, it is of paramount importance to assess
at what pain intensity patients have the impetus to take
medication for BTcP. Regardless of data extrapolated by
controlled studies where the driving force is imputable to
different factors, including the design and inclusion crite-
ria, to objectify the level of pain currently experienced at
which patients seek medication, it is necessary to gather
this information from patients who are educated and
trained in distinguishing the changes of pain intensity.
We can estimate that an admission time of 5 days,
during which patients experience 8–10 episodes, mainly
successfully treated, may be reliable to recognize the indi-
vidual threshold to ask for BTcP medication and the level
of pain intensity corresponding to acceptable pain control
with the drug and dose prescribed. In this paper, the mean
pain intensity at which patients feel the need for BTcP
medication was about 7/10 on a numerical scale. A reduc-
tion of approximately two points or a reduction of approx-
imately 30% of pain intensity has been reported to be a
clinically important difference8,12,13. It has been reported
that percentage change in pain ratings correlates better
with patient perception of benefit14. However, an impor-
tant clinical difference does not always correspond to
what a patient feels or expects. On the other hand
the higher baseline scores (for example the typical pain
intensity of a BTcP event) require larger raw changes to
represent a clinical important difference13. In this
paper patients presenting an episode of severe intensity
(on average 7 on a numerical scale of 0–10) were satisfied
with about a 50% pain decrease. These cut-off points
should be taken into account for future studies of drugs
used for BTcP.
Coping strategies may potentially influence the out-
come. However, no specific coping profile was associated
with the two levels of pain intensities chosen by patients.
The reason may relate to the poor capacity of the brief
COPE, which is disease-oriented, in this study setting.
Alternately, the training and education of patients, as
well as the friendly environment and positive communi-
cation may have flattened this aspect. This is also con-
firmed by the fact that concerns about the use of BTcP
medications were minimal, different from what was
observed in patients who did not receive adequate train-
ing2. This can reflect the positive experience of patients
about safety and effectiveness in the unit.
Conclusion
On the basis of the present observation, patients needing a
BTcP medication are likely to have a pain intensity of 7
on a numerical scale of 0–10, and patients who are satisfied
after receiving a BTcP medication are likely to have a pain
intensity of 4/10. This occurs in both cases in 77% of
patients. These cut-off points could help in selecting
patients in studies of BTcP, avoiding the inclusion of
patients with intermediate situations, which often contrib-
ute to misinterpretation of data reported in the literature.
Other studies performed in different settings, at home or in
outpatient clinics, and with a larger sample of patients,
should confirm this preliminary observation. Cultural dif-
ferences should be also explored.
Transparency
Declaration of funding
The authors received no payment in preparation of this
manuscript.
Declaration of financial/other relationships
S.M. has served on the Speakers Bureaus for Grunenthal, Janssen,
Teva, Molteni and ProStrakan. C.A., R.T., A.V., F.F., A.G., and
A.C. have disclosed that they have no significant relationships
with or financial interests in any commercial companies related
to this study or article.
CMRO peer reviewers may have received honoraria
for their review work. The peer reviewers on this manu-
script have disclosed that they have no relevant financial
relationships.
Acknowledgments
The authors are indebted to the nurses of the unit of La
Maddalena cancer center, and the staff of psycho-oncologists of
the University of Turin.
Table 4. The relationship between clinical variables and meaningful pain
intensity for Breakthrough cancer pain (BTcP).
Meaningful
pain
intensity
for BTcP P*
Meaningful
pain
intensity
after BTcP
medication P*
Gender 0.794 0.699
Age group (65/465) 0.597 0.330
Primary tumor 0.692 0.943
Education 0.690 0.341
Opioid for background analgesia 0.811 0.146
Opioid for BTcP 0.825 0.516
Brief coping profiles 0.674 0.495
*Univariate analysis of variance (ANOVA).
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